Characteristics of patients of the study and controls
. | Aspergillus . | . | CMV . | . | ||
|---|---|---|---|---|---|---|
. | Infused patients . | Controls . | Infused patients* . | Controls† . | ||
| No. of patients | 10 | 13 | 27 | 41 | ||
| Median age (range) | 30 (16-48) | 26 (17-62) | 33 (16-58) | 35 (16-63) | ||
| Diagnosis | ||||||
| AML | 4 | 8 | 14 | 26 | ||
| ALL | 2 | 3 | 6 | 6 | ||
| CML | 1 | 2 | 2 | 1 | ||
| MM | 0 | 0 | 3 | 0 | ||
| NHL | 2 | 0 | 2 | 0 | ||
| Disease status | ||||||
| I to II CR | 5 | 6 | 13 | 21 | ||
| More than II CR | 2 | 1 | 2 | 2 | ||
| Refractory disease | 2 | 4 | 10 | 17 | ||
| CML-CP | 0 | 0 | 1 | 1 | ||
| CML-AP | 1 | 1 | 1 | 0 | ||
| CML-BC | 0 | 1 | 0 | 0 | ||
| Conditioning regimen | ||||||
| TBI-based | 9 | 9 | 23 | 38 | ||
| Melphalan-based | 1 | 4 | 4 | 3 | ||
| Graft content | ||||||
| CD34, × 106/kg | 9.7 ± 1.2 | 12.5 ± 4.2 | 11.6 ± 2.6 | 12.0 ± 1.4 | ||
| CD3, × 104/kg | 0.8 ± 0.6 | 0.8 ± 0.6 | 1.0 ± 0.6 | 1.4 ± 0.1 | ||
. | Aspergillus . | . | CMV . | . | ||
|---|---|---|---|---|---|---|
. | Infused patients . | Controls . | Infused patients* . | Controls† . | ||
| No. of patients | 10 | 13 | 27 | 41 | ||
| Median age (range) | 30 (16-48) | 26 (17-62) | 33 (16-58) | 35 (16-63) | ||
| Diagnosis | ||||||
| AML | 4 | 8 | 14 | 26 | ||
| ALL | 2 | 3 | 6 | 6 | ||
| CML | 1 | 2 | 2 | 1 | ||
| MM | 0 | 0 | 3 | 0 | ||
| NHL | 2 | 0 | 2 | 0 | ||
| Disease status | ||||||
| I to II CR | 5 | 6 | 13 | 21 | ||
| More than II CR | 2 | 1 | 2 | 2 | ||
| Refractory disease | 2 | 4 | 10 | 17 | ||
| CML-CP | 0 | 0 | 1 | 1 | ||
| CML-AP | 1 | 1 | 1 | 0 | ||
| CML-BC | 0 | 1 | 0 | 0 | ||
| Conditioning regimen | ||||||
| TBI-based | 9 | 9 | 23 | 38 | ||
| Melphalan-based | 1 | 4 | 4 | 3 | ||
| Graft content | ||||||
| CD34, × 106/kg | 9.7 ± 1.2 | 12.5 ± 4.2 | 11.6 ± 2.6 | 12.0 ± 1.4 | ||
| CD3, × 104/kg | 0.8 ± 0.6 | 0.8 ± 0.6 | 1.0 ± 0.6 | 1.4 ± 0.1 | ||
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; CR, complete remission; CP, chronic phase; AP, accelerated phase; and BC, blastic crisis.
Twenty-five of 27 patients received donor type CMV-specific T-cell clones; 2 of 27 patients received host type CMV-specific T-cell clones
Thirty-three CMV-positive recipients who received transplants from CMV-positive donors; 8 CMV-positive recipients who received transplants from CMV-negative donors